Valuation dashboard for Telix Pharmaceuticals Limited (TLX) with P/E 95.01, P/B 6.32, EV/EBITDA 112.6 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
Analysis Summary
Telix Pharmaceuticals Limited reported revenue of $789.8M in the most recent fiscal year, growing at a 5-year CAGR of 172.9%.
Trailing-twelve-month margins: gross margin 52.1%, operating margin -0.8%, net margin 3.7%.
At $9.05 (closing price, November 2, 2026), TLX trades at a P/E of 95.01 and an ROE of 7.24%. Market capitalisation stands at $3.1B.
Balance sheet quality for TLX: debt-to-equity ratio of 1.19, current ratio of 2.01 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 95.01 |
| Price / Book | 6.32 |
| EV / EBITDA | 112.6 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| TLX | Telix Pharmaceuticals Limited | $3.1B | 95.01 | 6.32 | 7.2% |
| VRTX | Vertex Pharmaceuticals Incorporated | $140.2B | 35.60 | 4.28 | 17.5% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $99.0B | 21.24 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $88.2B | 12.93 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $55.0B | 41.27 | 6.54 | 16.9% |
| 0QNO.L | Lonza Group AG | CHF 43.8B | 5.43 | -1.3% |
Price
| Price | $9.05 (closing price, November 2, 2026) |
| Market Cap | $3.1B |
| Exchange | NASDAQ |
| Country | AU |
Profitability
| Return on Equity | 7.24% |
| Return on Invested Capital | -0.61% |
| Return on Assets | 2.40% |
| Gross Margin | 52.14% |
| Operating Margin | -0.78% |
| Net Margin | 3.69% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of TLX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks